NeuroBo Pharmaceuticals exclusive licenses NB-01 to MThera Pharma for diabetic neuropathy treatment.
NeuroBo Pharmaceuticals signs an exclusive license agreement with MThera Pharma, granting the rights to NB-01 for treating painful diabetic neuropathy. The agreement allows MThera to conduct research and clinical trials, including a potential Phase 3 trial in the US and South Korea, for future commercialization of NB-01. NeuroBo aims to focus on the continued development of DA-1726 and DA-1241.
July 30, 2024
3 Articles